Study summary
Deuruxolitinib restored most scalp hair in about 4 in 10
41.5%reached 80% or more scalp coverage on 12 mg
What was tested
Deuruxolitinib, a JAK1/2 pill, at 8 or 12 mg twice daily against placebo for adults with at least 50% scalp hair loss.
What they found
- 41.5% on 12 mg reached 80% or more scalp coverage at 24 weeks, vs under 1% with placebo.
- Most side effects were mild or moderate.
What it means
Approved in 2024 as Leqselvi.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.